Literature DB >> 9288574

Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells.

S S Solomon1, S K Mishra, C Cwik, B Rajanna, A E Postlethwaite.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) has recently been implicated as a cause of insulin resistance (IR) in obesity and non-insulin dependent diabetes mellitus (NIDDM). To examine mechanisms involved, we induced IR induced IR in H-411 E cells with graded doses of TNF-alpha and measured the ability of insulin (INS) to stimulate both calmodulin (CaM) mRNA and glucose utilization. With TNF-alpha concentration at 1 ng/ml and 10(4) muU/ml INS, metformin 10 microM and pioglitazone 1.5 microM, reversed the IR induced by TNF-alpha restoring biologic response to 100% of INS effect alone. Furthermore, comparable results were obtained with glucose utilization/oxidation experiments in the H-411 E cells using glucose U-14C, trapping 14CO2 release in a hyamine filter and extracting 14C labelled lipids with Dole's reagent. In condusion, these data add scientific support for the use of both metformin and pioglitazone in treatment of IR in NIDDM patients and support a rationale for use of use of these drugs alone, and in conjuction with oral agents and/or INS treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9288574     DOI: 10.1055/s-2007-979059

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  3 in total

Review 1.  Cytokines and the pathogenesis of non-alcoholic steatohepatitis.

Authors:  A M Diehl; Z P Li; H Z Lin; S Q Yang
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

Review 2.  Hepatic steatosis and type 2 diabetes mellitus.

Authors:  Jeanne M Clark; Anna Mae Diehl
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

3.  Metformin Associated With Improved Outcomes in Diabetic Patients With Laryngeal and Oropharyngeal Carcinoma.

Authors:  Amie Ogunsakin; Jordan Infield; Jeffery Zuber; Solomon S Solomon
Journal:  Am J Med Sci       Date:  2018-09-13       Impact factor: 2.378

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.